Search

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.

Read more

Chairs and Members

Chair:

Marc H. G. P. Raaijmakers, M. D. , Ph. D.

Read more

Chairs and Members

ChairPieter Sonneveld (Rotterdam, The Netherlands)

Members
Niels Abildgaard (Odense, Denmark)
Meral Beksac (Ankara, Turkey)
Luca Berthamini (Rotterdam, Netherlands)
Lenka Bešše, Brno (Czech Republic)
Dr Bila (Belgrade, Serbia)
Nicole Brolli (Milano, Italy)
Sara Bringhen (Turin, Italy)
Mario Boccadoro (Turin, Italy)
Anna Maria Brioli (Bologna, Italy)
Annemiek Broyl (Rotterdam, Netherlands)—also Chair of Young…

Read more

SWG Educational Activities

In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more

Highlights from the SWG

Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.

Read more

SWG Educational Activities

EHA Congress, Frankfurt 2023:

Guidelines presentation on anti-thrombotic treatment in hemophilia
SWG Symposium on Bleeding and Thrombosis

Joint webinar with the SWG on Thrombocytopenias and Platelet Function Disorders, October 2023.

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more